Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by M.D. Anderson Cancer Center
Incyte Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: December 14, 2012
Last updated: June 2, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: July 2019 (Final data collection date for primary outcome measure)